HER2-positive breast cancer brain metastases: multiple responses to systemic chemotherapy and trastuzumab - a case report
HER2-positive breast cancer brain metastases: multiple responses to systemic chemotherapy and trastuzumab - a case report
复制标题
DOI：
10.1007/s11060-006-9139-8
复制
发表时间：
2006-09-01
影响因子：
3.9
通讯作者：
Price, C. G. A.
中科院分区：
文献类型：
--
作者：
Church, D. N.;Bahl, A.;Price, C. G. A.
转移性乳腺癌的脑转移通常发生在10%-15%的患者中，并与3-6个月的生存有关。最近的一系列研究表明，接受曲妥珠单抗治疗的HER2阳性转移性乳腺癌患者发生脑转移的几率更高，但在这类患者被诊断为脑转移后继续使用曲妥珠单抗也与延长生存期有关。作者推测，这是由于改善了对疾病的系统控制；然而，曲妥珠单抗可能对脑转移瘤本身有有益的影响。我们报告了一例HER2阳性的转移性乳腺癌患者，她在使用曲妥珠单抗期间发生了多个脑转移，在继续曲妥珠单抗的基础上加上全身化疗，产生了与延长生存期相关的多种治疗反应。这是此类报告中的第一个。
Brain metastases from metastatic breast cancer typically occur in 10-15% of patients and are associated with survival of 3-6 months. Recent series have shown that women with HER2-postive metastatic breast cancer receiving the drug trastuzumab develop brain metastases more frequently than this, but also that continuation of trastuzumab after diagnosis of brain metastases in such patients is associated with extended survival. Authors have speculated that this is due to improved systemic control of disease; however, a possibility is that trastuzumab may have a beneficial effect on cerebral metastases themselves. We report the case of a woman with HER2-positive metastatic breast cancer who developed multiple brain metastases while on trastuzumab, in whom the addition of systemic chemotherapy to continued trastuzumab has produced multiple treatment responses associated with prolonged survival. This is the first report of its kind.